Here are the 424B prospectus supplements from Kardigan, Inc. (KARD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow KARD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KARD filings page.
Kardigan, Inc. is offering 25,000,000 shares of common stock at an initial public offering price of $16.00 per share, with gross proceeds of $400,000,000 and expected delivery on or about June 22, 2026. The underwriters have a 30‑day option to purchase up to an additional 3,750,000 shares at the IPO price less underwriting discounts and commissions.
The prospectus (dated June 17, 2026) states net proceeds to Kardigan before expenses of $372,000,000, and reserves up to 5% of the offering for directors, officers and certain employees under a directed share program. The prospectus also discloses pro forma common shares outstanding of 64,339,121 shares as of March 31, 2026 and summarizes the company’s clinical-stage cardiovascular pipeline and its Prolaio data platform.